Authors
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Kathryn Maples, PharmD, BCOP, on Key Considerations for Belantamab Mafodotin Administration in Multiple MyelomaA clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Key Takeaways in CAR-T Therapy for Multiple MyelomaPanelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.
Latest:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentZenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Latest:
Emergency Fertility Preservation in a Young Woman With Non-Hodgkin LymphomaA nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Latest:
Spinal ATRT and Radiotherapy Case Report in an Adult ManA rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.
Latest:
Clinical Pearls on CRS and ICANS Management in Multiple MyelomaModerator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Latest:
Patient Case Presentation: Patient on ESA for First-Line Therapy and Not Receiving a Marked Response—What Do You Do Next, and Why?Panelists discuss management strategies for a patient with low-risk myelodysplastic syndrome with erythropoiesis-stimulating agent (ESA) failure, weighing options between initiating luspatercept or escalating ESA dosage while emphasizing the need for thorough evaluation of reversible causes before advancing therapy.
Latest:
Data Show Inconsistent Biomarker Testing in Gastric/GEJ Cancer CareFindings highlight the challenge of evolving logistics for testing and related decision-making in the treatment of those with gastric or GEJ cancers.
Latest:
Looking Ahead in R/R FL: Unmet Needs and What’s NextPanelists discuss how unmet needs in relapsed/refractory follicular lymphoma (R/R FL), including durability of responses, adverse effect management, personalized treatment, resistance to therapy, and access to care, are driving exciting developments in emerging targeted therapies, improved CAR T technologies, combination approaches, and efforts to enhance access and affordability for patients.
Latest:
Clinical Data May Support PARP Inhibition in Somatic BRCA-Mutant TNBCBreast oncologist Jade E. Jones, MD, says she tries to send patients with HR-positive BRCA-mutant TNBC to clinical trials that use PARP inhibitors.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLCAdding aumolertinib to chemotherapy in the treatment of patients with EGFR-mutated NSCLC led to improvements in progression-free survival.
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Impact of Tobacco Cessation on the Development of Bladder CancerVikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
Sholl Examines Importance of Pathology in Cancer Care“You have to look at the cell-free DNA results with a grain of salt and with some degree of sophistication in terms of what you can act on as a predictive biomarker in the blood.”
Latest:
Expert Emphasizes Importance of Cancer Prevention and Screenings on World Cancer DayAn expert from Ochsner Health discusses the essential role positive lifestyle habits and regular screenings play in preventing cancer diagnoses.
Latest:
Adverse Effects Associated With JAK Inhibitors in MyelofibrosisNaveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.
Latest:
Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPCPhillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.
